The Motley Fool
06 Nov 2025, 17:02 UTC · 46w ago
Verdict
Headline takes no side. We score GKOS −0.30 across three claims — moderately bearish.
−0.30moderately bearish
More negative than 70% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Vericel Corporation reported third-quarter revenue of $67.5 million, a 17% increase year-over-year driven by MACI cartilage repair therapy growth.
More positive than 93% of claims this week
Brown Capital Management reduced its position in Vericel Corporation by 861,020 shares, valued at approximately $30.9 million.
So whatSignificant selling by an institutional manager can create downward price pressure and signal a lack of confidence in short-term valuation.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 86% of claims this week
Brown Capital Management's reductions in both Vericel and Glaukos suggest a defensive shift in its small-cap growth strategy.
More negative than 71% of claims this week
Which stocks this story touches
More negative than 70% of ticker scores this week
Mentioned as part of a defensive shift by Brown Capital Management, which reduced its position in the company.
More negative than 64% of ticker scores this week
The company faced a significant stake reduction by Brown Capital Management and has underperformed the S&P 500, despite strong Q3 revenue growth.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+83.6%
Price is moving against the score
$154.88 vs $84.35 close before publication (Nov 5) · not market-adjusted
GKOS chart →
